Most Comprehensive Tests for Diagnosing and Characterizing the Genomic Causes of Childhood Developmental Disorders, including Autism Spectrum Disorders

MUKILTEO, Wash., Jan. 26, 2009 — CombiMatrix Corporation (NasdaqGM:CBMX – News) announced today that its wholly owned subsidiary, Combimatrix Molecular Diagnostics (CMDX), has entered into a new partnership with Lenetix, a New York based laboratory, to co-market CMDX’s suite of array CGH based tests including the industry leading BAC HD Scan(tm) test, the most comprehensive test for characterizing genomic causes of childhood developmental disorders. The BAC HD Scan test can identify over 290 genomic causes of developmental disorders and is routinely used in postnatal genetic diagnostics. Also included in CMDX’s suite of developmental genomic tests is the Prenatal Scan array CGH test, a more customized test specifically designed and validated for use in prenatal genetic diagnostics. Both companies will launch their co-marketing endeavors at the upcoming Society of Maternal-Fetal Medicine 29th Annual Meeting in San Diego (Jan 26-30th, 2009).

“By accurately determining the genomic cause, or etiology, of an unprecedented number of childhood development disorders, and facilitating such diagnosis in as timely a manner as possible, the BAC HD Scan test removes the anxiety associated with undiagnosed cases of developmental delay, provides critical genomic information for the appropriate genetic counseling of parents and provides parents and caregivers the most data-driven expectation of clinical developmental outcome of their child. Our collaboration with Lenetix will help us increase awareness of our tests among primary care physicians including pediatricians, genetic counselors and obstetricians-gynecologists — key customers of Lenetix,’ said Dr. Mansoor Mohammed, President and Chief Executive Officer of Combimatrix Molecular Diagnostics.

“Lenetix prides itself on offering our clients and patients the most appropriate and rigorously validated tests in the pre- and postnatal genetic testing genre. CMDX’s portfolio of array CGH tests have become routine requisitions in the genetic diagnostic community and exceed our exacting standards,’ said Leonard Kellner, Lenetix’s President and CEO. “I firmly believe that these tests are indispensable additions to our pre- and postnatal product lines and will help us achieve our goal of always providing physicians with the best clinical genetics support services and technologies for optimal patient care.’

ABOUT THE BAC HD SCAN TEST

The BAC HD Scan test is the most comprehensive, clinically validated Constitutional Array Genetic Test in the industry. The test utilizes CMDX’s Bacterial Artificial Chromosome (BAC) array technology, and is comprised of 2,437 unique validated loci. It is designed to interrogate over 290 specific genes and genomic regions associated with over 260 known genetic disorders while enabling the detection of unexpected abnormalities with an industry-best average resolution of 432 Kb across the entire genome.

The test also provides the most comprehensive genome content for the unique subtelomeric and pericentromeric regions of all chromosomes — key areas often involved in the etiology of developmental disorders — making it a powerful tool for challenging cases. The list of 260 disorders can be reviewed at the following link: https://www.cmdiagnostics.com/docs/disordersname.pdf

The array also incorporates the probe content of CMDX’s ATScan(tm) for Autism Spectrum Disorder (ASD) and simultaneously interrogates all of the known genomic markers currently associated with ASD.